aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
Healthcare
$0.53 +14.23%
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
52W Low $0.40High $7.29
Volume 1.02M
Average 2.29M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$61.99M
FY 2025 · Annual
Investing Cash Flow
-$5.05M
FY 2025 · Annual
Financing Cash Flow
$66.01M
FY 2025 · Annual
+65.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.61M | 2.15M | 2.6M | 2.99M | 5M |
| Change in Working Capital | (2.59M) | (833K) | 15.01M | (6.92M) | 7.45M |
| Accounts Receivables | 1.6M | (11.92M) | 9.05M | 402K | 863K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 47K | 0 | 3.26M | (1.34M) | (33K) |
| Other Working Capital | (4.24M) | 11.09M | 2.7M | (5.98M) | 6.62M |
| Other Non-Cash Items | 363K | 441K | (3.19M) | (2.71M) | (1.87M) |
| Operating Cash Flow | (33.08M) | (41.89M) | (33.22M) | (69.12M) | (61.99M) |
| Capital Expenditures | (192K) | (1.64M) | (4.22M) | (65K) | (77K) |
| Acquisitions (Net) | 50K | 0 | 0 | 7K | 12K |
| Purchases of Investments | (126.51M) | (42.12M) | (106.98M) | (69.1M) | (93.45M) |
| Sales of Investments | 35.08M | 90.83M | 91.05M | 86.39M | 86.6M |
| Other Investing Activities | 0 | 179K | 15K | 0 | 1.85M |
| Investing Cash Flow | (91.57M) | 47.25M | (20.13M) | 17.23M | (5.05M) |
| Debt Repayment | 0 | (66K) | (394K) | (497K) | (539K) |
| Common Stock Issued | 109.95M | 5.47M | 66.52M | 40.26M | 66.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 73K | 45K | 105K | 100K | 0 |
| Financing Cash Flow | 110.03M | 5.45M | 66.23M | 39.86M | 66.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (14.62M) | 10.81M | 12.88M | (12.02M) | (1.03M) |
| Free Cash Flow | (33.27M) | (43.53M) | (37.44M) | (69.18M) | (62.06M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$74.1M
+ D&A$1.6M
+ Stock-Based Comp$5.0M
+ Deferred Tax$0
+ Working Capital$7.5M
- Other Non-Cash-$1.9M
= Operating Cash Flow-$62.0M
- Capex-$77.0K
= Free Cash Flow-$62.1M
Analysis
FY2025 free cash flow is -$62.1M. FCF conversion is 83.7% of net income. Operating cash flow was -$62.0M, with capex of -$77.0K. The largest bridge item is Working Capital at $7.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Aug 7, 2026 | |
| 8-K | Current report | Aug 7, 2026 | |
| 10-Q | Quarterly report | Aug 7, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 6, 2026 | |
| 8-K | Current report | Jul 31, 2026 |
Does ATYR generate free cash flow?
aTyr Pharma, Inc. (ATYR) generated -$62.06M of free cash flow in fiscal 2025.
How much operating cash flow does ATYR produce?
Operating cash flow was -$61.99M, before capital expenditures of $77,000.00.
Continue the stock analysis
Jump to another research area for this company.